Bacil Pharma Peer Comparison

Bacil Pharma Ltd. is significantly lagging behind its peers in key financial metrics such as revenue growth, profitability, and efficiency. With a PE ratio of 124.55 and no reported revenue or profit margins, it is not positioned favorably compared to the more established competitors in the pharmaceuticals sector.

• • Bacil Pharma Ltd. reported 0% revenue growth YoY and 3-Year, indicating stagnation.
• • The company has a very high PE ratio of 124.55 with no returns on equity (ROE = 0).
• • Compared to peers, Bacil Pharma is underperforming on profitability metrics and carries no debt.

• • Sun Pharmaceutical Industries Ltd.: Highest revenue growth (YoY 8.42%) and strong profitability with ROE of 16.13%.
• • Cipla Ltd.: Strong growth trajectory with 13.28% revenue growth YoY and a low PE ratio of 23.73.
• • Dr. Reddy's Laboratories Ltd.: Consistent profitability metrics with ROE of 21.76% and a low PE ratio of 15.50.